Joshua Rosenberg, MD
Critical Care Medicine · Brooklyn, NYNPI 1629264924
Payments from drug & device makers
Across 1,036 payments — averaging $850.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$449K
- Merck$173K
- Shionogi Inc$101K
- Aimmune Therapeutics, Inc.$76K
- La Jolla Pharmaceutical Company$31K
- Sanofi Pasteur Inc.$25K
- plus $27K from 14 others
What the payments were for
- Consulting fees$46,7095%
- Speaking & faculty fees$705,14880%
- Travel & lodging$103,31812%
- Food & beverage$26,0293%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 554 | $448,811 |
| Merck | 222 | $173,009 |
| Shionogi Inc | 99 | $101,411 |
| Aimmune Therapeutics, Inc. | 46 | $75,595 |
| La Jolla Pharmaceutical Company | 42 | $31,060 |
| Sanofi Pasteur Inc. | 24 | $24,741 |
| Tetraphase Pharmaceuticals, Inc. | 23 | $22,963 |
| Paratek Pharmaceuticals, Inc. | 3 | $1,031 |
| Melinta Therapeutics, LLC | 4 | $708 |
| Pfizer | 4 | $537 |
| CSL Behring | 3 | $382 |
| AstraZeneca(2 entities) | 3 | $349 |
| Sanofi | 2 | $244 |
| Astellas Pharma US Inc | 1 | $125 |
| Gilead | 1 | $124 |
| Accelerate Diagnostics Inc. | 1 | $65 |
| Terumo Medical Corporation | 1 | $33 |
| Irhythm Technologies, Inc. | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVYCAZ$241,922
- ZERBAXA$96,806
- Fetroja$96,232
- EMBLAVEO$76,773
- ZENPEP$75,250
- Xerava$48,573
- RECARBRIO$42,972
- DALVANCE$36,911
- TEFLARO$36,863
- FLUZONE HIGH-DOSE$14,677
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$9,746
- ADACEL$5,220
- XACDURO$2,724
- Zevtera$1,678
- DISEASE STATE$1,664
- NUZYRA$1,005
- FLUZONE QUADRIVALENT$870
- Vabomere$525
- Kcentra$382
- DILTIAZEM HYDROCHLORIDE$370
How this compares
$881,262 in reported general payments places this provider in the 95th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Brooklyn
- Saleem ShahzadBrooklyn$38K
- Mohammad ZamanBrooklyn$13K
- Daniel BuchneaBrooklyn$10K
- Yizhak KupferBrooklyn$8K
- Chetana PendkarBrooklyn$7K
- Liziamma GeorgeBrooklyn$5K
- Steven BadinBrooklyn$5K
- Samir FahmyBrooklyn$4K
- Max O DonnellNew York$1.7M
- Roxana SulicaNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.